The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options

J Hepatol. 2018 Dec;69(6):1365-1370. doi: 10.1016/j.jhep.2018.08.013. Epub 2018 Aug 23.

Abstract

Background & aims: Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis and NASH-related cirrhosis from a cohort with longitudinal follow-up data.

Methods: Patients with cryptogenic cirrhosis or NASH cirrhosis were screened for a clinical trial. Patients with <5% hepatic steatosis regardless of other histologic features were considered to have cryptogenic cirrhosis. Clinico-laboratory data and adjudicated liver-related events (e.g. decompensation, qualification for transplantation, death) were available.

Results: A total of 247 patients with cirrhosis (55.3 ± 7.4 years, 37% male) were included; 144 had NASH cirrhosis and 103 had cryptogenic cirrhosis. During a median follow-up of 29 (IQR 21-33) months (max 45 months), 20.6% of patients had liver-related clinical events. Patients with NASH cirrhosis and cryptogenic cirrhosis were of a similar age and gender, as well as having a similar body mass index, PNPLA3 rs738409 genotype, and prevalence of diabetes (p >0.05). However, patients with cryptogenic cirrhosis had higher serum fibrosis markers and greater collagen content and α-smooth muscle actin expression on liver biopsy. Compared to cirrhotic patients with NASH, patients with cryptogenic cirrhosis experienced significantly shorter mean time to liver-related clinical events (12.0 vs. 19.4 months; p = 0.001) with a hazard ratio of 1.76 (95% CI 1.02-3.06).

Conclusions: Populations with NASH and cryptogenic cirrhosis have similar demographics, but patients with cryptogenic cirrhosis have evidence of more active fibrosis and a higher risk of liver-related clinical events. Thus, we believe these patients belong to the same spectrum of disease, with cryptogenic cirrhosis representing a more advanced stage of fibrosis.

Lay summary: Significant liver damage and cirrhosis of the liver may develop without a known cause - a liver disease referred to as cryptogenic cirrhosis. In this work we found that, in the presence of metabolic abnormalities, cryptogenic cirrhosis may actually be a part of the non-alcoholic fatty liver disease spectrum. Yet, it appears to be more progressive than typical non-alcoholic fatty liver disease, leading to advanced liver disease at a faster rate.

Keywords: Cryptogenic cirrhosis; Fatty liver; NAFLD; NASH; Outcomes.

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / analysis
  • Aged
  • Biopsy
  • Collagen / analysis
  • Diabetes Mellitus / epidemiology
  • Disease Progression
  • Female
  • Fibrosis
  • Follow-Up Studies
  • Genotype
  • Humans
  • Liver / pathology
  • Liver Cirrhosis / congenital*
  • Liver Cirrhosis / epidemiology
  • Longitudinal Studies
  • Male
  • Metabolic Syndrome / epidemiology
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / epidemiology*
  • Outcome Assessment, Health Care*
  • Prevalence
  • Prospective Studies

Substances

  • ACTA2 protein, human
  • Actins
  • Collagen

Supplementary concepts

  • Cirrhosis, Cryptogenic